Science Updates

FDA Approves Camizestrant Combination Regimen for Locally Advanced or Metastatic Breast Cancer

Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600–Mutant Advanced Melanoma

Total Neoadjuvant Therapy With Long-Course Radiotherapy Versus Chemoradiotherapy in High-Risk Locally Advanced Rectal Cancer (TNTCRT): A Multicenter, Randomized, Phase III Trial

FDA approves zidesamtinib for ROS1-positive non-small cell lung cancer

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase IIb KEYNOTE-942 Study

On-treatment serum prostate-specific antigen and overall survival in prostate cancer (STAMPEDE platform protocol): a post-hoc analysis of data from five phase 3 trials

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Assessment of survival benefit from sentinel node biopsy for melanoma: a systematic review and meta-analysis